Table 2.

Consensus recommendations for patients using BoNT for the cosmetic treatment of various indications in the lower face.

Authors	Indication
	Perioral		Gummy Smile		Masseter Hypertrophy		Parotid Gland Hypertrophy		DAO		Cobble Stone Chin
	Total Dose (U)	IP (n)	Total Dose (U)	IP (n)	Total Dose (U)	IP (n)	Total Dose (U)	IP (n)	Total Dose (U)	IP (n)	Total Dose (U)	IP (n)
	Dose per IP (U)		Dose per IP (U)		Dose per IP (U)		Dose per IP (U)		Dose per IP (U)		Dose per IP (U)
Carruthers et al., 2004, 2008 [33,34]	4–5	2–6	2–4	1/side	25–30/side	NR	NR	NR	2–5	1/side	4–5	1–2
Carruthers et al., 2013 [35]	4–6	2–6	NR	NR	NR	NR	NR	NR	1–15	1/side	4–10	1–2
									1–7.5
Raspaldo et al., 2011 [38,39]	Up: 2–5 L: 2–5	Up: 2–4 L: 2–4	3–5/side	1/side	18–30/side	1–5/side	NR	NR	2–5/side	1–2/side	6–10	2
	~1		1–2		6				1–2.5		3–5
Maas et al., 2012 [44]	5 (range: 2–12)	Up: 4 L: 2	5 (range: 2–10)	1/side	32.5 (range: 20–60)	3/side	NR	NR	6 (range: 2–10)	1/side	5 (range: 3–10)	2–3
Imhof et al., 2013 [45]	4	Up: 4 L: 2	NR	NR	4–6	2 or 3	NR	NR	1–3	1/side	6 (range: 2–8)	2
					2
Lorenc et al., 2013 [46]	5	2	NR	NR	NR	NR	NR	NR	5	1/side	4–5	2
	2.5								2.5
Yuskovskaya et al., 2015 [43]	Up: 4–6	Up: 4	NR	NR	50	3/side	NR	NR	6	1/side	6	2
	1–1.5				2				3		3
Sundaram et al., 2016 [47,48]	1–5	2–5	1–4, 8	1–2/side	15–40	1–5/side	NR	NR	2–4/side	1–2/side	4–10	1–4
	0.5–1		0.5–2		5–15				2		2–3
De Maio et al., 2017 [49,50,51]	Up: 2–4 L: 2	U: 2–4 L: 2	6–10	3–5	6–24/side	3/side	NR	NR	4–8	1/side	4–8	1- 3
	1		2		4–8				2–4		2.5
Kaminer et al., 2020 [52]	2–10	2–8	NR	NR	5–35	2–6/side	NR	NR	2–6	1–2/side	2–10	1–4
Signorini et al., 2022 [53]	1–4	Up: 2–4	6–10	3	25–50/side	3–5/side	NR	NR	4–8	1/side	8–10	1–2
	0.5–1		2		5–10 or 7–22				2–4		4–10

U, unit; IP, injection point; n, number; F, female; M, male; NR, not reported; Up, upper lip; L, lower lip.